Trending...
- Pennsylvania: Gov. Wolf Recognizes Grocery Store Workers, Now Vaccine Eligible, for Heroic Work
- Children's Hospital of Philadelphia's Dr. N. Scott Adzick Receives Clinical and Translational Science Distinguished Investigator Award for Bringing Fetal Surgery from the Lab to the Clinic
- TVS Main Street Network Returns Petticoat Junction to Tuesday Nights on WatchYour.TV Platform
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation ("HSAC", "Immunovant", or the "Company") (NASDAQ: IMVT) securities between October 2, 2019 and February 1, 2021, inclusive (the "Class Period"). Immunovant investors have until April 20, 2021 to file a lead plaintiff motion.
Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. ("Legacy Immunovant") to effect a merger between the two entities (the "Merger").
Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is Phase IIa clinical trials for the treatment of myasthenia gravis ("MG") and thyroid eye disease ("TED"). The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia ("WAIHA").
More on The PennZone
On February 2, 2021, the Company issued a press release "announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401." The Company also disclosed that it "has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients" and "[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program."
On this news, the Company's stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased Immunovant securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. ("Legacy Immunovant") to effect a merger between the two entities (the "Merger").
Immunovant is developing IMVT-1401, a novel fully human monoclonal antibody, which is Phase IIa clinical trials for the treatment of myasthenia gravis ("MG") and thyroid eye disease ("TED"). The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia ("WAIHA").
More on The PennZone
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ebang International Holdings, Inc. (EBON) Investors
- Fifty States of Vodka is Now Available in Every Total Wine In Florida
- TVS Classic Sports Network Adds Iconic College Football Classics to Program Schedule on WatchYour.TV
- BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting
- Mensa Foundation Celebrates 50 Years of Unleashing Intelligence
On February 2, 2021, the Company issued a press release "announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401." The Company also disclosed that it "has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients" and "[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program."
On this news, the Company's stock price fell $18.22 per share, or 42.08%, to close at $25.08 per share on February 2, 2021, thereby injuring investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Atos SE (AEXAY) on Behalf of Investors
- Gary S. Monroe, C.D. Accelerates Promising New Treatments For Cocaine And Methamphetamine Addicts
- Pennsylvania: Gov Wolf Applauds President on Gun Safety Orders, Calls on General Assembly to Take Action
- Survey reveals a third of U.S. homeowners experienced a utility interruption during the COVID-19 pandemic as 19.5 million Americans plan digging projects this spring
- ExpressCells Completes Series A2 Financing
If you purchased Immunovant securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- Julia Hair Spring Sale Up To 46% Off With Buy Now Pay Later
- CB Insights Again Names AI.Reverie a Top 100 AI Startup
- PQ Group Holdings to Host Virtual Investor Conference on Thursday, April 8, 2021 at 10:00 ET; Focus will be Target PQ, a High Growth Pure-Play Catalyst and Services Company
- Ismail Sirdah's Helpful Tips For Selling Event Ticket Online
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ubiquiti Inc. (UI) on Behalf of Investors
- Sandline Global Broadens Commitment to Data & Analytics: Adam Poeppelmeier Joins as Director of Business Intelligence
- The Savory Grape Launches New Online Shopping And Delivery Experience
- Covid-19 Quarantine Spawns 18 "Pregnancy After 40" Birth Announcements From Group Members in a Single Week
- Waypoint Orthopedics Today Announced the Appointment of Jeffrey F. O'Donnell, Jr. as President
- Spencer, Okla., Selects Inframark for Its Water, Wastewater Operations
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ebang International Holdings, Inc. (EBON) on Behalf of Investors
- Pennsylvania: Gov. Wolf Recognizes Grocery Store Workers, Now Vaccine Eligible, for Heroic Work
- Massage Therapy Center in Los Angeles is Putting a Spring Back In Your Step
- Multi-platinum singer Linda Varg and Audilus to join forces
- COE Distributing Names New President, Restructures for Long-term Growth
- Social Security The Great Ponzi Scheme: "If This Book Doesn't Raise Your Blood Pressure, You'd Better Check For A Pulse!"
- National Minority Health Association Launches PSA to Increase Vaccine Confidence in Minority Communities
- Comcast Business and Versa Networks Drive Further SD-WAN Innovation on ActiveCore℠ Platform
- DeRonja Real Estate Welcomes Mackenzie Seiter
- TVS Main Street Network Returns Petticoat Junction to Tuesday Nights on WatchYour.TV Platform